Investegate |Formycon AG Announcements | Formycon AG: Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG

Investegate announcements from Formycon AG, Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG

Related Keywords

Germany ,Australia ,Japan ,United States ,Munich ,Bayern ,Frankfurt Am Main ,Hessen ,Poland ,Canada ,German ,Carsten Brockmeyer ,Wendeln Cie ,Bioeq Gmb ,Stefan Glombitza ,Melissa Simon ,Florian Bamberg ,Aristo Pharma Gmb ,Bioeq Gmbh ,Genentech Inc ,Research Development ,Strategic Communications ,Santo Holding Gmb ,Corporate Communications ,Formycon Group ,Johnson ,Press Release ,Santo Holding Gmbh ,Aristo Pharma Gmbh ,Nicolas Comb ,Active Ownership Capital ,Executive Board ,Supervisory Board ,Active Ownership ,Audio Webcast ,Manager Corporate Communications ,Investegate Announcements ,Investegate Company Announcements ,Formycon Ag ,Qs ,Qs And Eqs ,